{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:22:55Z","timestamp":1793395375661,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK135937-01A1"],"award-info":[{"award-number":["R01DK135937-01A1"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R03DK129631"],"award-info":[{"award-number":["R03DK129631"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007028","name":"Leona M. and Harry B. Helmsley Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","cghjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.cgh.2024.06.050","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T13:19:53Z","timestamp":1723555193000},"page":"454-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"title":["Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8618-7635","authenticated-orcid":false,"given":"David I.","family":"Fudman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A.","family":"McConnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2024.06.050_bib1","doi-asserted-by":"crossref","first-page":"55","DOI":"10.14309\/ajg.0000000000002485","article-title":"A\u00a0review of available medical therapies to treat moderate-to-severe inflammatory bowel disease","volume":"119","author":"Chang","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib2","author":"Gros"},{"key":"10.1016\/j.cgh.2024.06.050_bib3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/ibd\/izab011","article-title":"Real-world effectiveness and safety of tofacitinib in patients with ulcerative colitis: systematic review with meta-analysis","volume":"28","author":"Taxonera","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.050_bib4","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/ibd\/izad165","article-title":"1-year comparison of clinical and endoscopic outcomes of tofacitinib vs vedolizumab for ulcerative colitis after anti-tumor necrosis factor failure: a real-world cohort study in the United States","volume":"30","author":"Dalal","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.050_bib5","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/apt.17305","article-title":"Real-world comparison of effectiveness between tofacitinib and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent","volume":"57","author":"Buisson","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.06.050_bib6","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2022.04.038","article-title":"Superior effectiveness of tofacitinib compared to vedolizumab in anti-TNF-experienced ulcerative colitis patients: a nationwide Dutch registry study","volume":"21","author":"Straatmijer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib7","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/ueg2.12492","article-title":"Comparison between tofacitinib and ustekinumab as a third-line therapy in refractory ulcerative colitis: a multicenter international study","volume":"12","author":"Allocca","year":"2024","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.cgh.2024.06.050_bib8","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.cgh.2023.03.001","article-title":"Upadacitinib is effective and safe in both ulcerative colitis and Crohn\u2019s disease: prospective real-world experience","volume":"21","author":"Friedberg","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib9","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000002746","article-title":"One-year comparative effectiveness of upadacitinib vs tofacitinib for ulcerative colitis: a multicenter cohort study","author":"Dalal","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib10","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/ecco-jcc\/jjac157","article-title":"Multicentre real-world experience of upadacitinib in the treatment of Crohn\u2019s disease","volume":"17","author":"Chugh","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib11","doi-asserted-by":"crossref","first-page":"i620","DOI":"10.1093\/ecco-jcc\/jjac190.0621","article-title":"P491 Efficacy and safety of upadacitinib for the treatment of fistulas and fissures in patients with Crohn\u2019s disease","volume":"17","author":"Colombel","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib12","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/j.cgh.2022.11.029","article-title":"Upadacitinib therapy reduces ulcerative colitis symptoms as early as day 1 of induction treatment","volume":"21","author":"Loftus","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","article-title":"Tofacitinib induction therapy reduces symptoms within 3 days for patients with ulcerative colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib14","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.14309\/ajg.0000000000002263","article-title":"Comparative speed of early symptomatic remission with advanced therapies for moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"118","author":"Ahuja","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib15","doi-asserted-by":"crossref","first-page":"i102","DOI":"10.1093\/ecco-jcc\/jjac190.0078","article-title":"DOP38 upadacitinib therapy reduces Crohn\u2019s disease symptoms within the first week of induction therapy","volume":"17","author":"Colombel","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib16","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.cgh.2020.10.038","article-title":"Efficacy and safety of extended induction with tofacitinib for the treatment of ulcerative colitis","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/cpt.576","article-title":"Model-informed development and registration of a once-daily regimen of extended-release tofacitinib","volume":"101","author":"Lamba","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.06.050_bib18","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1016\/j.cgh.2023.05.001","article-title":"Real-world experience with tofacitinib dose de-escalation in patients with moderate and severe ulcerative colitis","volume":"21","author":"Yu","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib19","doi-asserted-by":"crossref","first-page":"861","DOI":"10.14309\/ajg.0000000000002129","article-title":"REMIT-UC: real-world effectiveness and safety of tofacitinib for moderate-to-severely active ulcerative colitis: a Canadian IBD Research Consortium Multicenter National Cohort Study","volume":"118","author":"Ma","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib20","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/ecco-jcc\/jjaa249","article-title":"Outcomes of tofacitinib dose reduction in patients with ulcerative colitis in stable remission from the randomised RIVETING trial","volume":"15","author":"Vermeire","year":"2021","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib21","doi-asserted-by":"crossref","first-page":"i914","DOI":"10.1093\/ecco-jcc\/jjac190.0911","article-title":"P781 Treatment outcome of tofacitinib dose reduction to 5 mg BID vs remaining on 10 mg BID in patients with ulcerative colitis who were in stable remission on 10 mg BID: updated 30-month data from the double-blind, randomised RIVETING study","volume":"17","author":"Rubin","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/apt.17816","article-title":"Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis","volume":"59","author":"Panaccione","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.06.050_bib23","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.14309\/01.ajg.0000859860.18839.f9","article-title":"S805 efficacy of upadacitinib dose escalation in a phase 3 long-term extension ulcerative colitis study","volume":"117","author":"Panaccione","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib24","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2024.06.050_bib25","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","article-title":"Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance","volume":"82","author":"Kristensen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2024.06.050_bib27","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","article-title":"Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the Global Clinical Programme","volume":"17","author":"Sandborn","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib28","doi-asserted-by":"crossref","first-page":"i644","DOI":"10.1093\/ecco-jcc\/jjac190.0648","article-title":"P518 Safety of upadacitinib in ulcerative colitis: long-term data from the phase 3 open-label extension study (U-ACTIVATE)","volume":"17","author":"Panaccione","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib29","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cgh.2023.09.033","article-title":"Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis","volume":"22","author":"Mattay","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib30","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1007\/s10620-022-07404-z","article-title":"Comparative risk of thrombotic and cardiovascular events with tofacitinib and anti-TNF agents in patients with inflammatory bowel diseases","volume":"67","author":"Kochar","year":"2022","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2024.06.050_bib31","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.050_bib32","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/annrheumdis-2021-220822","article-title":"Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2024.06.050_bib34","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/apt.17379","article-title":"Systematic review with network meta-analysis: risk of herpes zoster with biological therapies and small molecules in inflammatory bowel disease","volume":"57","author":"Din","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.06.050_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.cgh.2024.06.050_bib36","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.1379","article-title":"N07 JAKne: JAK inhibitor associated acne, a real-life single-center experience","volume":"18","author":"De Dycker","year":"2024","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib37","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jamadermatol.2023.3830","article-title":"Janus kinase inhibitors and adverse events of acne: a systematic review and meta-analysis","volume":"159","author":"Martinez","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib38","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jaad.2022.06.012","article-title":"Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: a post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials","volume":"87","author":"Mendes-Bastos","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib39","first-page":"34","article-title":"Reproductive safety issues of novel small molecules for the treatment of inflammatory bowel disease: a systematic review","volume":"13","author":"Monfared","year":"2023","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cgh.2024.06.050_bib40","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41575-023-00758-3","article-title":"Inflammatory bowel disease in pregnancy and breastfeeding","volume":"20","author":"Brondfield","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib41","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): a randomized controlled trial","volume":"119","author":"Singh","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib42","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ecco-jcc\/jjad036","article-title":"Tofacitinib for acute severe ulcerative colitis: a systematic review","volume":"17","author":"Steenholdt","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib43","doi-asserted-by":"crossref","DOI":"10.14309\/ajg.0000000000002674","article-title":"Effectiveness of upadacitinib for patients with acute severe ulcerative colitis: a multi-center experience","author":"Berinstein","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib44","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.14309\/ajg.0000000000002676","article-title":"Rates of adverse events in patients with ulcerative colitis undergoing colectomy during treatment with tofacitinib vs biologics: a multicenter observational study","volume":"119","author":"Dragoni","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib45","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/acr.24893","article-title":"2022 American College of Rheumatology\/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty","volume":"74","author":"Goodman","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.cgh.2024.06.050_bib46","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1007\/s10067-020-04956-1","article-title":"Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis","volume":"39","author":"Kaine","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib47","doi-asserted-by":"crossref","first-page":"921","DOI":"10.14309\/ajg.0000000000002139","article-title":"A\u00a0practical guide to use of risankizumab","volume":"118","author":"Horst","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib48","doi-asserted-by":"crossref","first-page":"400","DOI":"10.14309\/ajg.0000000000002531","article-title":"A\u00a0practical guide to the use of mirikizumab","volume":"119","author":"Barnes","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib49","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"D\u2019Haens","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.06.050_bib50","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.06.050_bib51","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izad315","article-title":"Real-world effectiveness and safety of risankizumab in patients with moderate to severe multirefractory Crohn\u2019s disease: a Belgian multicentric cohort study","author":"Alsoud","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.050_bib52","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/apt.17358","article-title":"Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn\u2019s disease: a GETAID multicentre cohort study","volume":"57","author":"Fumery","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2024.06.050_bib53","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.cgh.2023.11.033","article-title":"Risankizumab effectiveness and safety in Crohn\u2019s disease: real-world data from a large tertiary center","volume":"22","author":"Zinger","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib54","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0000995740.88073.c5","article-title":"S1 risankizumab versus ustekinumab in patients with moderate to severe Crohn\u2019s disease: results from the phase 3B SEQUENCE trial","volume":"118","author":"Peyrin-Biroulet","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib55","doi-asserted-by":"crossref","first-page":"S624","DOI":"10.14309\/01.ajg.0000953020.05891.05","article-title":"S845 risankizumab induction therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomized phase 3 INSPIRE study","volume":"118","author":"Louis","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib56","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/ecco-jcc\/jjad212.0006","article-title":"OP06 risankizumab maintenance therapy in patients with moderately to severely active ulcerative colitis: efficacy and safety in the randomised phase 3 COMMAND study","volume":"18","author":"Louis","year":"2024","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib57","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as induction and maintenance therapy for ulcerative colitis","volume":"388","author":"D\u2019Haens","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2024.06.050_bib58","doi-asserted-by":"crossref","first-page":"i62","DOI":"10.1093\/ecco-jcc\/jjad212.0035","article-title":"OP35 efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn\u2019s disease: results from the phase 3 VIVID 1 study","volume":"18","author":"Jairath","year":"2024","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib59","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn\u2019s disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib60","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the treatment of Crohn\u2019s disease: induction results from the phase 2 GALAXI-1 study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.050_bib61","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(23)04757-1","article-title":"913b The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active ulcerative colitis: results from the phase 3 QUASAR induction study","volume":"164","author":"Allegretti","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.050_bib62","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjab232.124","article-title":"DOP85 Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn\u2019s disease and inadequate response to risankizumab maintenance therapy","volume":"16","author":"Baert","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib63","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1093\/ibd\/izae020.192","article-title":"Risankizumab dose escalation in patients with Crohn\u2019s disease","volume":"30","author":"Nichols","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.050_bib64","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/ecco-jcc\/jjad206","article-title":"Risankizumab induction therapy achieves early symptom improvements that are associated with future clinical and endoscopic outcomes in Crohn\u2019s disease: post hoc analysis of the ADVANCE, MOTIVATE, and FORTIFY phase 3 studies","volume":"18","author":"Colombel","year":"2024","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib65","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/ecco-jcc\/jjad168","article-title":"Maintenance risankizumab sustains induction response in patients with Crohn\u2019s disease in a randomized phase 3 trial","volume":"18","author":"Ferrante","year":"2024","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib66","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0000859660.28064.8c","article-title":"S755 early symptom control with mirikizumab in patients with moderately to severely active ulcerative colitis in the LUCENT-1 induction trial","volume":"117","author":"Danese","year":"2022","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib67","article-title":"Risk of infection in patients with inflammatory bowel disease treated with interleukin-targeting agents: a systematic review and meta-analysis","author":"Ouranos","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.050_bib68","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjd.20818","article-title":"Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis","volume":"186","author":"Gordon","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib69","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.cgh.2022.10.029","article-title":"Comparative safety and effectiveness of biologic therapy for Crohn\u2019s disease: a CA-IBD cohort study","volume":"21","author":"Singh","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib70","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","article-title":"Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib71","doi-asserted-by":"crossref","first-page":"S-1114","DOI":"10.1016\/S0016-5085(23)03577-1","article-title":"Tu1762 risankizumab levels are significantly correlated and predictive of biomarker remission in Crohn\u2019s disease","volume":"164","author":"Barrau","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.050_bib72","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s40262-023-01281-z","article-title":"Mirikizumab pharmacokinetics in patients with moderately to severely active ulcerative colitis: results from phase III LUCENT studies","volume":"62","author":"Chua","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cgh.2024.06.050_bib73","doi-asserted-by":"crossref","first-page":"468","DOI":"10.14309\/ajg.0000000000002553","article-title":"Maternal and neonatal outcomes in vedolizumab and ustekinumab exposed pregnancies: results from the PIANO registry","volume":"119","author":"Chugh","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib74","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/ecco-jcc\/jjac086","article-title":"Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal, and infant outcome: a prospective multicentre study","volume":"16","author":"Mitrova","year":"2022","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib75","first-page":"691","article-title":"Postoperative outcomes after preoperative ustekinumab exposure in patients with Crohn\u2019s disease: a systematic review and meta-analysis","volume":"34","author":"Garg","year":"2021","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib76","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2665-9913(23)00120-0","article-title":"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study","volume":"5","author":"Papp","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib77","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nri2400","article-title":"The alliance of sphingosine-1-phosphate and its receptors in immunity","volume":"8","author":"Rivera","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cgh.2024.06.050_bib78","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2024.06.050_bib79","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.14309\/01.ajg.0000798724.11932.76","article-title":"P031 impact of prior biologic exposure on response to ozanimod for moderate-to-severe ulcerative colitis in the phase 3 True North study","volume":"116","author":"Sands","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2024.06.050_bib80","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s10620-023-08178-8","article-title":"Real world clinical effectiveness and safety of ozanimod in the treatment of ulcerative colitis: 1-year follow-up from a tertiary center","volume":"69","author":"Cohen","year":"2024","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2024.06.050_bib81","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.06.050_bib82","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/ecco-jcc\/jjad112","article-title":"Clinician\u2019s guide to using ozanimod for the treatment of ulcerative colitis","volume":"17","author":"Sands","year":"2023","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2024.06.050_bib83","series-title":"Zeposia (ozanimod) [package insert]","year":"2021"},{"key":"10.1016\/j.cgh.2024.06.050_bib84","series-title":"Velsipity (etrasimod) [package insert]","year":"2023"},{"key":"10.1016\/j.cgh.2024.06.050_bib85","series-title":"Velspity. [Summary of product characteristics.]","year":"2023"},{"key":"10.1016\/j.cgh.2024.06.050_bib86","first-page":"1678","article-title":"Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature","volume":"269","author":"Sriwastava","year":"2022","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.cgh.2024.06.050_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103675","article-title":"A\u00a0comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients","volume":"59","author":"Sharma","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.cgh.2024.06.050_bib88","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1177\/1352458513500551","article-title":"Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy","volume":"20","author":"Francis","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.cgh.2024.06.050_bib89","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.cgh.2023.11.018","article-title":"Cardiovascular safety of ozanimod in patients with ulcerative colitis: True North and Open-Label extension analyses","volume":"22","author":"Armuzzi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib90","doi-asserted-by":"crossref","DOI":"10.1093\/ibd\/izae011","article-title":"Pregnancy outcomes in the ozanimod clinical development program in patients with ulcerative colitis, Crohn\u2019s disease, and relapsing multiple sclerosis","author":"Dubinsky","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2024.06.050_bib91","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000832","article-title":"Ozanimod maintenance therapy after cyclosporine induction in acute severe ulcerative colitis","volume":"9","author":"Cohen","year":"2022","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.cgh.2024.06.050_bib92","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2024.06.050_bib93","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2024.06.050_bib94","article-title":"Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis","author":"Burr","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2024.06.050_bib95","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib96","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.gastro.2023.12.005","article-title":"Pharmacoequity for older adults with inflammatory bowel diseases","volume":"166","author":"Kochar","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2024.06.050_bib97","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1007\/s10620-023-08098-7","article-title":"Insurance approval delay of biologic therapy dose escalation associated with disease activity in patients with inflammatory bowel disease","volume":"68","author":"Shah","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2024.06.050_bib98","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-052501","article-title":"Delays related to prior authorization in inflammatory bowel disease","volume":"149","author":"Constant","year":"2022","journal-title":"Pediatrics"},{"key":"10.1016\/j.cgh.2024.06.050_bib99","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.cgh.2023.06.021","article-title":"Prior authorizations delay therapy, impact decision-making, and lead to adverse events in inflammatory bowel disease: 2022 Provider Survey","volume":"22","author":"Constant","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2024.06.050_bib100","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.cgh.2024.01.050","article-title":"White Paper: American Gastroenterological Association Position Statement: the future of IBD care in the United States - removing barriers and embracing opportunities","volume":"22","author":"Sofia","year":"2024","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524007286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356524007286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T20:23:16Z","timestamp":1739305396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356524007286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":99,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1542356524007286"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2024.06.050","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2024.06.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the AGA Institute","name":"copyright","label":"Copyright"}]}}